News Archive

December 2016

• Media ReleaseDec 16, 2016

  Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited

  Acquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline    Investigational…
• In The NewsDec 15, 2016

  Confronting the next global health challenge

  Novartis Chairman Joerg Reinhardt says the successful fight against infectious diseases in poor countries provides valuable lessons for the emerging crisis of chronic diseases.
• Media ReleaseDec 12, 2016

  Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines

  SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health  Program uses smartphones and…
• Media ReleaseDec 12, 2016

  Novartis lance SMS for Life 2.0 au Nigeria pour aider à améliorer l'accès aux médicaments essentiels

  SMS for Life 2.0 est lancé pour la première fois dans l'Etat de Kaduna, troisième région la plus peuplée du Nigeria, en collaboration avec le ministère de la Santé de l'Etat de Kaduna. Ce…
• Media ReleaseDec 12, 2016

  Novartis führt "SMS for Life 2.0" in Nigeria ein, um den Zugang zu unentbehrlichen Arzneimitteln zu verbessern

  "SMS for Life 2.0" wird zum ersten Mal im Bundesstaat Kaduna, der bevölkerungsreichsten Region Nigerias, in Zusammenarbeit mit dem Gesundheitsministerium von Kaduna eingeführt. Das Programm nutzt…
• Media ReleaseDec 12, 2016

  Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)

  Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care…
• Media ReleaseDec 09, 2016

  Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole

  MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone  …
• Media ReleaseDec 08, 2016

  Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment

  Ultibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies   Results further support the…
• Media ReleaseDec 07, 2016

  Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions

  The European Commission approved Lucentis to treat patients for visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular…
• Media ReleaseDec 06, 2016

  Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC

  Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC[1]  Patients with…
• Featured NewsDec 06, 2016

  Health experts explore response to chronic illness in poor countries

  Health experts from around the world met November 29 to discuss ways to tackle an emerging crisis.

• Media ReleaseDec 05, 2016

  Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®

  ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients[1] The Tasigna TFR trials, including ENESTop, demonstrate our continued…